Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.62 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.60 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.56 |
| ▸ | APLNR | P35414 | 1/20 | 0.56 |
| ▸ | REN | P00797 | 2/20 | 0.55 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Amide SCHEMBL29619836 | 1.00 | C5AR1 (0.62) | C5AR1AGTR2AGTR1EPHA2APLNR | |
| SCHEMBL29976758 | 0.97 | AGTR2 (0.65) | C5AR1AGTR2AGTR1EPHA2APLNR | |
| [Val5] - Angiotensin Ii SCHEMBL29551599 | 0.97 | AGTR2 (0.64) | C5AR1AGTR2AGTR1EPHA2APLNR | |
| SCHEMBL29976469 | 0.95 | C5AR1 (0.65) | C5AR1AGTR2AGTR1EPHA2APLNR | |
| SCHEMBL29619803 | 0.95 | C5AR1 (0.65) | C5AR1AGTR2AGTR1EPHA2APLNR | |
| SCHEMBL29701253 | 0.94 | C5AR1 (0.64) | C5AR1AGTR2AGTR1EPHA2APLNR | |
| SCHEMBL31544391 | 0.94 | AGTR1 (0.62) | C5AR1AGTR2AGTR1APLNRNMUR2 | |
| Angiotensin Ii SCHEMBL9013950 | 0.94 | AGTR2 (0.69) | C5AR1AGTR2AGTR1EPHA2APLNR | |
| Angiotensin Ii SCHEMBL9013957 | 0.94 | AGTR2 (0.69) | C5AR1AGTR2AGTR1EPHA2APLNR | |
| Angiotensin Ii SCHEMBL22125774 | 0.94 | AGTR2 (0.69) | C5AR1AGTR2AGTR1EPHA2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021571-B1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-10-08 | — | — | EP | disclosed |
| EP-3607962-B1 | ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION | THE GEORGE WASHINGTON UNIV A CONGRESSIONALLY CHARTERED NOT FOR PROFIT CORPORATION (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4552649-A2 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-05-14 | — | — | EP | disclosed |
| CN-119700926-A | Angiotensin II alone or in combination for the treatment of hypotension | 乔治华盛顿大学国会特许非营利公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240197812-A1 | Methods of Treating Cardiac Injury | PROLETARIAT THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| EP-3400000-B1 | METHODS FOR ADMINISTERING ANGIOTENSIN II | LA JOLLA PHARMA LLC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230226141-A1 | ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION | THE GEORGE WASHINGTON UNIV A CONGRESSIONALLY CHARTERED NOT FOR PROFIT CORPORATION (US) | 2023-07-20 | — | — | US | disclosed |
| US-11583568-B2 | Methods for administering angiotensin II | LA JOLLA PHARMA, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| US-11559559-B2 | Angiotensin II alone or in combination for the treatment of hypotension | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220307065-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-09-29 | — | — | US | disclosed |
| US-20220273757-A1 | METHODS FOR ADMINISTERING ANGIOTENSIN II BY MONITORING RENIN LEVELS | LA JOLLA PHARMA LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-20220211798-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-07-07 | — | — | US | disclosed |
| US-20220193183-A1 | COMPOSITIONS AND METHODS FOR TREATING RENAL FAILURE | LA JOLLA PHARMA, LLC | 2022-06-23 | — | — | US | disclosed |
| US-20220047669-A1 | ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211798-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF | DPP3, ACE, FABP3 | C5AR1 116/4885AGTR2 9/4885AGTR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.